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SUMMARY 
The role of inhibition of prelamin A processing in the inhi- thesis was assessed. It was found that expression of 
bition of DNA synthesis by lovastatin was examined by prelamin A specifically conferred sensitivity to inhibition 
expressing prelamin A in F9 teratocarcinoma cells. These of DNA biosynthesis by lovastatin on F9 cells. 
cells, normally lacking expression of the A/C lamins, were 
transfected with constructs expressing either prelamin A or Key words: protein prenylation, lovastatin, lamin A, DNA synthesis, 
mature lamin A and the effect of lovastatin on DNA biosyn- prelamin A 
INTRODUCTION 
It has been known for some time that starvation of mammalian 
cells for mevalonate produces an inhibition of DNA biosyn­
thesis and an eventual cell cycle arrest (Quesney-Huneeus et 
al., 1979). Initial studies on a few cell lines showed that inhi­
bition of mevalonate biosynthesis by means of the 3-hydroxy­
3-methylglutaryl coenzyme A reductase inhibitors (Habernicht 
et al., 1980; Fairbanks et al., 1984), compactin or lovastatin, 
or by mutation of HMG-CoA synthase (Sinensky and Logel, 
1985) resulted in blocks early in G1, and later studies extended 
this observation to a large number of permanent cell lines 
(Keyomarski et al., 1991). The discovery of proteins post­
translationally modified with the isoprenoids farnesyl and ger­
anylgeranyl (Schmidt et al., 1984; Rilling et al., 1990) led to 
the suggestion (Sinensky et al., 1985) that a decline in level of 
the prenylated form of one of these proteins during mevalonate 
starvation might be responsible for the cell cycle arrest. 
Intriguing candidates for this role are the farnesylated, p21ras 
proteins. However, studies with cells expressing a mutant 
p21ras, whose biological activity is farnesylation-independent, 
showed that these cells still exhibited sensitivity of DNA 
synthesis to mevalonate starvation (DeClue et al., 1991). 
Another possible candidate protein, which could be respon­
sible for the inhibition of DNA biosynthesis that follows 
mevalonate starvation, is prelamin A. We have previously 
shown that prelamin A undergoes a farnesylation-dependent 
removal of a carboxyl-terminal peptide (Beck et al., 1990) that 
blocks assembly of lamin A into the nuclear lamina (Lutz et 
al., 1992). Remarkably, lamin A molecules lacking this 
carboxyl-terminal domain are competent for assembly into the 
lamina. The lack of a functional requirement for farnesylation 
in assembly, other than to remove a domain inhibitory for 
assembly, suggests that this processing event may be of regu­
latory significance. 
Cells treated with lovastatin accumulate prelamin A in the 
nucleoplasm (Lutz et al., 1992), an observation that was pre­
viously seen with the mutant prelamin A that is incompetent 
for farnesylation (Holtz et al., 1989). Considering the proposed 
interaction between the nuclear lamina and chromatin in the 
interphase nucleus (Burke, 1990; Glass and Gerace, 1990; 
Paddy et al., 1990; Yuan et al., 1991), it is a plausible hypoth­
esis that this mislocalized prelamin A could be responsible for 
some of the effects of mevalonate starvation on DNA 
synthesis. 
To examine the role of prelamin A in the loss of DNA 
synthesis in response to mevalonate starvation it would be 
useful to compare isogenic cell lines that express or do not 
express prelamin A. A model for this situation has been 
described that takes advantage of the lack of expression of the 
A/C lamin proteins in stem cell tumor lines such as the mouse 
F9 teratocarcinoma (Lebel et al., 1987). The F9 cell has been 
transiently transfected with the human prelamin A cDNA and 
demonstrated to assemble this heterologous lamin A into the 
nuclear lamina (Collard and Raymond, 1990). In this report we 
describe the isolation of F9 cell lines that possess dexametha­
sone-inducible prelamin A or mature lamin A. The effects of 
prelamin A accumulation in cells starved for mevalonate by 
lovastatin treatment can now be determined relative to cells 
expressing only mature lamin A. The results are consistent 
with a substantial increase in sensitivity of cellular DNA 
synthesis to mevalonate starvation when prelamin A accumu­
lation can occur in response to lovastatin treatment. 
MATERIALS AND METHODS 
Cells, transfections and media 
The cells used in these studies were F9 mouse teratocarcinoma cells 
(ATCC CRL 1720). Cells are grown in DMEM supplemented with 
10% fetal calf serum or charcoal-stripped fetal calf serum. These cells 
have been reported previously to lack detectable expression of the 
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A/C lamins (Collard and Raymond, 1990), but we confirmed that this 
was the case (data not shown) by indirect immunofluorescence with 
a pan-species-specific anti-A/C lamin antibody, LS-1 (McKeon et al., 
1983). The dexamethasone-inducible pMMLA and pMMLAΔ21 con­
structs used for transfection have been described previously (Lutz et 
al., 1992; Sinensky et al., 1994). Permanent transfectants were 
selected by co-transfection with pSV2neo (Southern and Berg, 1982) 
using the Lipofectin method as described by the manufacturer 
(Gibco/BRL). G418-resistant clones were picked and screened for 
dexamethasone-inducible lamin A by indirect immunofluorescence 
with a primary anti-human lamin A antibody, 1E4 (Loewinger and 
McKeon, 1988), as described previously (Lutz et al., 1992). 
Effect of lovastatin on cholesterol biosynthesis 




















dish. Cells were incubated in various concentrations of lovastatin for 
1 hour and then 20 µCi of [3H]acetate (sodium salt) (DuPont-New 
England Nuclear, Waltham, MA; specific activity = 22 Ci/mmol) was 
added per plate. The cells were incubated for 17 hours and the lipids 
extracted with hexane:isopropyl alcohol (3:2, v/v), saponified and the 
non-saponifiable material was isolated as described previously (Panini 
et al., 1989). Radioactive cholesterol was isolated by thin-layer chro­
matography on silicic acid-coated plates (LK5D, Whatman, Hillsboro 
OR), developed with petroleum ether:acetone (90:10, v/v) and visu­
alized by fluorography after spraying with ENHANCE (New England 
Nuclear, Waltham, MA). The radioactive cholesterol bands were 
scraped from the plates into scintillation vials and quantified by liquid 
scintillation counting. 
Immunoprecipitation of p21ras 
Cell labeling with 35S (Tran35S-label, specific activity ≥ 1000 Ci/mmol 
(ICN, Costa Mesa, CA), harvesting and lysis were essentially as 
described previously (Leonard et al., 1990) except for the culture 
medium being DMEM. Ras protein was immunoprecipitated as 
described previously (Leonard et al., 1990) except that a different pan 
Ras mouse monoclonal antibody (ab3, Oncogene Sciences, Uniondale 
NY) was used. 
Rate of DNA bµiosynthesis 
Cells (2.5×105) were incubated for 1 hour with 1 µCi/ml of [methyl­
3H]thymidine (ICN, Irvine CA; specific activity = 20 Ci/mmol). The 
label incorporated into DNA was determined by precipitation with 
ice-cold trichloroacetic acid, collection of the precipitate on GFA, 
glass fiber filters (Whatman, Hillsboro OR) and quantification by 
liquid scintillation counting. Protein was determined by the method 
of Schacterle and Pollack (1973). 
RESULTS 
The sensitivity of mevalonate biosynthesis to 
lovastatin in F9 cells is comparable to that in other 
mammalian cell lines but that of DNA biosynthesis 
is not 
Lovastatin is a potent inhibitor of mevalonate biosynthesis in 
most cultured mammalian cells with an IC50 of less than 10−8 
M (~4 ng/ml), based on the incorporation of labeled acetate 
into cholesterol. We examined the effect of lovastatin on the 
incorporation of acetate into cholesterol in F9 cells. The results 
(Fig. 1) indicate a sensitivity of cholesterol synthesis in F9 cells 
to lovastatin comparable to that seen with other cultured 
mammalian cells (Sinensky et al., 1990). This observation 
demonstrates that neither the uptake of lovastatin nor its inhi­
bition of HMG-CoA reductase are less efficient than that 
observed for other mammalian cells. 
Fig. 1. Dose-response curve of cholesterol biosynthesis in F9 cells to 
lovastatin. The cells were incubated with [3H]acetate and 
incorporation into cholesterol was determined as described in 
Materials and Methods. The IC50 for inhibition of cholesterol 
biosynthesis by lovastatin in these cells is seen to be less than 5 
ng/ml. 
a 
Fig. 2. Effect of lovastatin (1 µg/ml) on the maturation of F9 cell 
p21ras. Immunoprecipitated p21ras is detected by labeling to 
metabolic equilibrium by means of an overnight incubation with 
[35S]methionine and cysteine. Untreated cells (−) exhibit a band that 
migrates with a 21.5 kDa molecular mass marker (soybean trypsin 
inhibitor). The formation of this p21ras is blocked by treatment with 
lovastatin (+) during the labeling period, resulting in the 
accumulation of the p21ras precursor (pro-p21ras). 
We also determined the activity of lovastatin as an inhibitor 
of protein prenylation by examining its effects on the process­
ing of p21ras. The results (Fig. 2) indicate that a concentration 
of 1 µg/ml lovastatin produces a substantial inhibition of 
p21ras processing in F9 cells, which is comparable to its effects 
on the processing of p21ras in other cell lines we have 
examined (Sinensky et al., 1990). 
Most mammalian cells studied thus far also exhibit an inhi­
bition of DNA biosynthesis in response to treatment with lovas­
tatin (Keyomarski et al., 1991). However, despite the sensitivity 
of mevalonate biosynthesis in F9 cells to lovastatin comparable 
to that seen with other cell-lines (the CHO-K1 cell line, for 
example), we find that F9 cells are remarkably resistant to inhi­
bition of DNA biosynthesis by lovastatin (Fig. 3). CHO-K1 
cells, like F9 cells, have an IC50 for inhibition of acetate incor­
poration into cholesterol of ~5 ng/ml and show marked inhibi­
tion of labeled methionine incorporation into mature p21ras 
when treated with 1 µg/ml lovastatin (Sinensky et al., 1990). 
Expression of prelamin A but not mature lamin A 
renders F9 cellular DNA synthesis sensitive to 
lovastatin 
We wished to test the hypothesis proposing that the lack of 
sensitivity of F9 cells to inhibition of DNA biosynthesis by 
lovastatin might be due to the absence of accumulation of 
prelamin A in these cells during the treatment with lovastatin. 
Prelamin A inhibits DNA synthesis 2217 
Lovastatin to the accumulation of unprocessed prelamin A. 
Cell type CHO-K1 F9 Since cells that are treated with doses of lovastatin sufficient 
Therefore, we transfected F9 cells with a prelamin A construct 
that we have described previously (Sinensky et al., 1994), 
which permits the dexamethasone induction of prelamin A 
expression in transfected cells. Since the nucleoplasmic local­
ization of prelamin A is farnesylation-dependent (Lutz et al., 
1992), we also wished to determine whether there was a dif­
ference in response to lovastatin by cells expressing only 
mature lamin A as opposed to those expressing only the 
prelamin A precursor. Thus, we also prepared transfectants that 
express a dexamethasone-inducible mature lamin A using 
another previously described construct, pMMLAΔ21 (Lutz et 
























pMMLA Δ21 constructs, co-transfected with the selectable 
neoR gene and the resultant G418-resistant clones were 
screened by indirect immunofluorescence with an anti-A/C 
lamin antiserum. Immunofluorescence detection of transfec­
tants is demonstrated in Fig. 4. As we have previously reported 
for both pMMLA and pMMLAΔ21 (Sinensky et al., 1994; 
Lutz et al., 1992), no expression was detected by indirect 
immunofluorescence in cells transfected with these constructs 
in the absence of dexamethasone treatment (data not shown). 
We now examined these transfectants that express prelamin 
A or mature lamin A for sensitivity of DNA synthesis to lovas­
tatin. The results (Fig. 5) are consistent with an increase in the 
sensitivity of DNA synthesis to lovastatin relative to the 
parental F9 cells in cells that express prelamin A (F9LA) but 
not in those that express mature lamin A (F9LAΔ21). Control 
experiments demonstrated that dexamethasone treatment had 
no effect on DNA synthesis in F9 cells or on DNA synthesis 
in F9LA cells in the absence of lovastatin (data not shown). 
DISCUSSION 
It has been observed for many cell types that lovastatin 
treatment produces an inhibition of cell growth. For cells 
growing in the presence of serum lipoproteins, this phenome­
non has been ascribed to a deficit in protein prenylation 
(Sinensky and Logel, 1985). The data reported here are con­
sistent with the hypothesis that, at least in part, the inhibition 
of DNA biosynthesis observed in lovastatin-treated cells is due 
Fig. 3. Effect of lovastatin (1 µg/ml) on the rate of DNA synthesis in 
F9 cells. Cells are incubated with [3H]thymidine for 1 hour after 
incubation for 28 hours in the presence (+) or absence of lovastatin 
(−). Incorporation of [3H]thymidine into DNA is measured as 
trichloroacetic acid-insoluble material. A lovastatin responsive cell-
line (CHO-K1) is shown for comparison. 
to completely block farnesylation arrest in early G1 (Jakobisiak 
et al., 1991), expression of non-farnesylated prelamin A would 
have to produce the same effect were it to be solely responsible 
for the effects of lovastatin. We and others (Lutz et al., 1992; 
Holtz et al., 1989) have demonstrated that non-farnesylated 
prelamin A, although still transported to the nucleus, is not 
Fig. 4. Expression of human lamin A and prelamin A in F9 cells. Clones expressing a construct encoding mature lamin A (B) and prelamin A 
(C) under control of a dexamethasone-inducible promotor (MMTV) are visualized by indirect immunofluorescence with an anti-lamin A/C 
antibody as described in Materials and Methods. Non-transfected F9 cells are shown for comparison (A). Cells in all three experiments were 
treated with 10−7 M dexamethasone, which induces the lamin protein in the transfectants. 
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Glass, J. R. and Gerace, L. (1990). Lamins A and C bind and assemble at the 
surface of mitotic chromosomes. J. Cell Biol. 111, 1047-1057. 













in Habenicht, A. J. R., Glomset, J. A. and Ross, R. (1980). Relation of 
cholesterol and mevalonic acid to the cell cycle in smooth muscle and Swiss 
3T3 cells stimulated to divide by platelet-derived growth factor. J. Biol. 
Chem. 255, 5134-5140. 
Holtz, D., Ranaka, R. A., Hartwig, J. and McKeon, F. (1989). The CaaX 
motif of lamin A functions in conjunction with the nuclear localization signal 
to target assembly to the nuclear envelope. Cell 59, 969-977. 
Jakobisiak, M., Bruno, S., Kierski, J. S. and Darzynkiewicz, Z. (1991). Cell 
cycle specific effects of lovastatin. Proc. Nat. Acad. Sci. USA 88, 3628-3632. 
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., 
McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D. and 
Marsters, J. C. Jr (1993). Benzodiazepine peptidomimetics: potent 
inihibitors of ras farnesylation in animal cells. Science 260, 1937-1942.
Cell type 
Keyomarski, K., Sandoval, L., Band, V. and Pardee, A. B. (1991). 
Synchronization of tumor and normal cells from G1 to multiple cell cycles byFig. 5. Expression of prelamin A, but not mature lamin A, renders 
DNA biosynthesis in F9 cells sensitive to lovastatin (1 µg/ml). DNA 
biosynthesis is measured as the incorporation of [3H]thymidine into 
trichloroacetic acid-insoluble material. Cells are incubated as 
lovastatin. Cancer Res. 51, 3602-3609. 
Kohl, N. E., Mosser, S. D., de Solms, J., Giuliani, E. A., Popliano, D. L., 
Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A. and Gibbs, J. B. 
(1993). Selective inhibition of ras-dependent transformation by a
described in the legend to Fig. 3 and the inhibition is reported as a farnesyltransferase inhibitor. Science 260, 1934-1937. 
percentage of the non-lovastatin-treated control. 
assembled into the lamina but rather is localized to the nucleo­
plasm. It is intriguing to speculate that this mislocalization of 
prelamin A may be responsible for its effects on DNA biosyn­
thesis. If prelamin A accumulation blocks cells in G1, it might do 
so by inhibiting the activity of protein factors, such as cyclins, 
that regulate G1 traverse (Sherr, 1993). On the other hand, 
prelamin A accumulation might directly inhibit DNA biosynthe­
sis through effects on DNA replication factors and, hence, block 
cells in S-phase. In either case, it is possible that the inhibition of 
DNA synthesis produced by prelamin A accumulation may be of 
regulatory significance and help to explain the puzzling func­
tional role of farnesylation in prelamin A processing. 
These observations regarding the effects of prelamin A accu­
mulation on DNA biosynthesis should also be considered in 
another context. It has recently been suggested that farnesyl 
protein transferase inhibitors might be useful as anti-malig­
nancy compounds through their activity in blocking the pro­
cessing of oncogenic pro-p21ras (Kohl et al., 1993; James et 
al., 1993). In light of the studies reported herein, it would be 
of interest to examine the effects of these compounds on 
prelamin A processing, since the inhibition of DNA biosyn­
thesis, produced by the accumulation of prelamin A, might 
contribute to the efficacy of such compounds in blocking 
cellular proliferation. 
This work was supported by ACS grant BD-29F to M.S. 
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